GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Cyclically Adjusted PB Ratio

CRXM (Gene Biotherapeutics) Cyclically Adjusted PB Ratio : (As of Sep. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Gene Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Gene Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Cyclically Adjusted PB Ratio Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gene Biotherapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Gene Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's Cyclically Adjusted PB Ratio falls into.



Gene Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Gene Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2020 is calculated as:

For example, Gene Biotherapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2020 was:

Adj_Book=Book Value per Share/CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-0.096/109.8968*109.8968
=-0.096

Current CPI (Dec. 2020) = 109.8968.

Gene Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
200912 -0.781 91.111 -0.942
201003 1.878 91.821 2.248
201006 1.947 91.962 2.327
201009 1.185 92.162 1.413
201012 1.788 92.474 2.125
201103 1.387 94.283 1.617
201106 0.977 95.235 1.127
201109 0.604 95.727 0.693
201112 1.260 95.213 1.454
201203 1.671 96.783 1.897
201206 1.358 96.819 1.541
201209 1.282 97.633 1.443
201212 0.985 96.871 1.117
201303 0.650 98.209 0.727
201306 0.643 98.518 0.717
201309 0.510 98.790 0.567
201312 0.134 98.326 0.150
201403 0.074 99.695 0.082
201406 0.090 100.560 0.098
201409 -0.028 100.428 -0.031
201412 -0.132 99.070 -0.146
201503 -0.170 99.621 -0.188
201506 -0.225 100.684 -0.246
201509 -0.259 100.392 -0.284
201512 -0.288 99.792 -0.317
201603 -0.318 100.470 -0.348
201606 -0.570 101.688 -0.616
201609 -0.173 101.861 -0.187
201612 -0.229 101.863 -0.247
201703 -0.260 102.862 -0.278
201712 -0.334 104.011 -0.353
201812 -0.358 105.998 -0.371
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 -0.296 108.420 -0.300
202003 -0.306 108.902 -0.309
202006 -0.184 108.767 -0.186
202009 -0.110 109.815 -0.110
202012 -0.096 109.897 -0.096

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gene Biotherapeutics  (OTCPK:CRXM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Gene Biotherapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367